Study of ORIC-944 in Patients With Metastatic Prostate Cancer
← catalyst calendarNCT05413421 · readout ≤ 315 d
Sponsored by ORIC Pharmaceuticals (industry) · ORIC — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
275estimated
Sites
27
Countries
Australia, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-01 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2022-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Prostate Cancer
Interventions
- Drug: ORIC-944
- Drug: Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
- Drug: Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Drug: Darolutamide (Nubeqa®) 300 mg tablets
- Drug: Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Primary outcomes
what the primary-completion date above is the date OFRecommended Phase 2 Dose (RP2D)
measured 12 months
Maximum plasma concentration (Cmax)
measured 28 Days
Time to maximum observed concentration (Tmax)
measured 28 Days
Area under the curve (AUC)
measured 28 Days
Apparent plasma terminal elimination half-life (t1/2)
measured 28 Days
Permalink · ORIC's whole pipeline · Catalyst calendar · Every registered study · What changed